BioSpace News Archive

An experimental compound reduced complications of type 1 and type 2 diabetes in mice – not by lowering blood sugar – but by countering its consequences: cell death, inflammation, and organ damage.

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx Conference on Thursday, Dec. 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 76,000 shares of the Company’s common stock at an exercise price per share of $48.47, which was the closing price on November 23, 2021.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 327,700 shares of its common stock to ten new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2022 ended September 30, 2021.